Examining the Effects of Stimulant Medication on Emotional Lability in Patients with ADHD
ADHD MRI Study for Stimulant Medication
Sponsor: New York State Psychiatric Institute
Enrolling: Male and Female Patients
IRB Number: 7261R
U.S. Govt. ID: NCT01415440
Contact: Susie Hong: 646-774-5863 / hongsus@nyspi.columbia.edu
Additional Study Information: In this study, we are trying to learn more about how stimulant medication produces an improvement in emotional lability (frequent mood changes and excessive emotional reactions) in patients with Attention Deficit Hyperactivity Disorder (ADHD.) Although ADHD is primarily associated with inattention, hyperactivity, and impulsivity, emotional ability plays a crucial role in the disorder. The study involves psychiatric evaluations, magnetic resonance imaging (MRI) scans, and treatment with either a medication called Vyvanse (lisdexamfetamine dimesylate) or a placebo (a pill with no active drug ingredient). Vyvanse is approved by the Food and Drug Administration (FDA) for treatment of ADHD. Participants will be compensated for their time.
This study is closed
Jonathan Posner, MD
Do You Qualify?
(If under 18) Has your child taken psychostimulants for 1 month or longer, and/or has had psychostimulants within past 4 months? Yes No
(If over the age of 18) Have you taken psychostimulants in the past 12 months? Yes No
Does your child have any non-removable metal on or in their body, e.g., pacemaker or braces? Yes No
Are you/your child 6-25 years of age? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Susie Hong